Tamoxifen, raloxifene, and the prevention of breast cancer.

@article{Jordan1999TamoxifenRA,
  title={Tamoxifen, raloxifene, and the prevention of breast cancer.},
  author={Virgil Craig Jordan and Monica Morrow},
  journal={Endocrine reviews},
  year={1999},
  volume={20 3},
  pages={
          253-78
        }
}
I. Introduction II. Lacassagne’s Prevention Principle: A Target and an Estrogen Antagonist III. Tamoxifen as an Antitumor Agent A. ER status and the duration of tamoxifen B. Contralateral breast cancer C. Endometrial cancer D. Conclusions IV. Selective Estrogen Receptor Modulation A. Antiestrogen activity at the ER B. Coactivators for ER C. Alternate response elements on DNA D. An alternate ER-ERβ V. Biological Basis for Tamoxifen as a Breast Cancer Preventive A. Animal models B. Bones C… Expand
Tamoxifen prevention of breast cancer: an instance of the fingerpost.
TLDR
The BCPT is assessed, the crowning achievement of positive studies of tamoxifen prevention, as an instance of the fingerpost for resolving the intense debate on the future direction of chemoprevention research. Expand
Therapeutic targeting in the estrogen receptor hormonal pathway.
TLDR
Elucidation of the gene networks and cell signaling pathways under estrogen and SERM regulation and a clearer definition of the respective roles of ER-alpha and ER-beta and their coregulators in the actions of selective ER ligands should enable the identification of new gene targets for therapeutic intervention and the development of novel drugs for the optimal treatment and prevention of breast cancer. Expand
Progress in the prevention of breast cancer: concept to reality
  • V. Jordan
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2000
TLDR
The recognition that nonsteroidal antiestrogens have the ability to modulate estrogen action selectively has advanced the design and development of new drug for multiple diseases. Expand
Raloxifene in breast cancer prevention
TLDR
A literature search to review available preclinical and clinical data that has led to the recent FDA approval of raloxifene as a chemopreventive agent for breast cancer in postmenopausal women indicated that ral oxifene is effective in reducing invasive breast cancer risk in post menopausal women. Expand
Chemoprevention of breast cancer.
TLDR
Tamoxifen has a proven safety record from analysis of its use in patients with early stage breast cancer and, in postmenopausal women, it maintains bone density and lowers cholesterol levels, and it reduces the incidence of contralateral breast cancer in women with breast cancer. Expand
Chemoprevention of breast cancer
TLDR
The aromatase inhibitors are superior to tamoxifen in reducing the recurrence of breast cancer in postmenopausal women; large clinical trials are currently evaluating the chemopreventive effect of these agents. Expand
Breast Cancer Prevention
TLDR
Tamoxifen is currently the only agent approved by the US Food and Drug Administration for chemoprevention in breast cancer but has not produced a survival advantage to date. Expand
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes
TLDR
Results support the potential of CE/BZA for the relief of menopausal symptoms and prevention of postmenopausal osteoporosis combined with breast and endometrial safety. Expand
Quimioprevenção do câncer de mama
TLDR
Positive results of several recent clinical trials for preventing breast cancer in high-risk populations suggest that chemoprevention is a rational and attractive strategy. Expand
The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
TLDR
Low-dose estrogen could be used to debulk patients followed by fulvestrant in a low estrogen environment (aromatase treatment) to maintain tumor control and suggest a rational approach for the treatment of patients with ER-positive breast cancer that have failed exhaustive antihormonal treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 301 REFERENCES
Prevention of breast cancer.
TLDR
It remains to be seen whether tamoxifen will act as a true preventive agent or whether it will merely delay the appearance of breast cancer, in which case the use of the drug may alter the natural history of the disease in women who have been exposed to tamoxIFen. Expand
Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme.
TLDR
The pilot trial has confirmed the findings of the feasibility study of tamoxifen and the frequency of side-effects was similar in both groups, except for a significant increase in hot flushes in the tamoxIFen-treated women. Expand
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
TLDR
In this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent and it is essential to continue follow-up to quantify the long-term risks and benefits of tamxifen therapy. Expand
Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.
TLDR
The combination of 9cRA and raloxifene, which has a high binding affinity for the estrogen receptor and a low level of estrogenic activity and does not promote growth of uterine epithelium, was evaluated for its chemopreventive activity in the well-accepted rat model of breast cancer induced by the carcinogen nitrosomethylurea. Expand
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease. Expand
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
TLDR
In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined. Expand
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
TLDR
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo. Expand
Tamoxifen in the Treatment of Breast Cancer
TLDR
Tamoxifen was approved by the Food and Drug Administration in 1977 for the treatment of women with advanced breast cancer and several years later for adjuvant treatment of primary breast cancer. Expand
Effect of tamoxifen on endometrial proliferation.
TLDR
Evidence is provided that the DNA flow cytometric hyperdiploid fraction may be a useful tool for monitoring endometrial cell proliferation in women exposed to tamoxifen, and this effect appears to be mediated by the stromal component. Expand
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
TLDR
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides. Expand
...
1
2
3
4
5
...